Agios Pharmaceuticals (AGIO) Operating Income: 2012-2025
Historic Operating Income for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$116.9 million.
- Agios Pharmaceuticals' Operating Income fell 13.67% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$475.6 million, marking a year-over-year decrease of 16.86%. This contributed to the annual value of -$425.7 million for FY2024, which is 8.75% down from last year.
- Per Agios Pharmaceuticals' latest filing, its Operating Income stood at -$116.9 million for Q3 2025, which was up 8.02% from -$127.1 million recorded in Q2 2025.
- In the past 5 years, Agios Pharmaceuticals' Operating Income ranged from a high of -$90.6 million in Q1 2023 and a low of -$127.1 million during Q2 2025.
- Over the past 3 years, Agios Pharmaceuticals' median Operating Income value was -$105.8 million (recorded in 2024), while the average stood at -$106.2 million.
- Per our database at Business Quant, Agios Pharmaceuticals' Operating Income crashed by 111.19% in 2021 and then rose by 10.41% in 2023.
- Over the past 5 years, Agios Pharmaceuticals' Operating Income (Quarterly) stood at -$104.8 million in 2021, then rose by 5.39% to -$99.2 million in 2022, then decreased by 7.16% to -$106.3 million in 2023, then declined by 17.65% to -$125.0 million in 2024, then declined by 13.67% to -$116.9 million in 2025.
- Its Operating Income was -$116.9 million in Q3 2025, compared to -$127.1 million in Q2 2025 and -$106.6 million in Q1 2025.